Clinical outcomes of hematopoietic stem cell transplantation for angioimmunoblastic T-cell lymphoma.
10.3760/cma.j.issn.0253-2727.2019.07.007
- Author:
Ling Min XU
1
;
Nai Nong LI
2
;
Zhao WANG
3
;
Xiao Xiong WU
4
;
Yu Jun DONG
5
;
Xiao Rui FU
6
;
Yao LIU
7
;
Liang Ding HU
8
;
Xiao Fan LI
2
;
Yi Ni WANG
3
;
Ya Mei WU
4
;
Han Yun REN
5
;
Ming Zhi ZHANG
6
;
Mai Hong WANG
7
;
Yu Hang LI
8
;
Wen Rong HUANG
1
Author Information
1. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.
2. Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Union Hospital of Fujian Medical University, Fuzhou 350001, China.
3. Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
4. Department of Hematology, Chinese PLA 304 Hospital, Beijing 100037, China.
5. Department of Hematology, Peking University First Hospital, Beijing 100034, China.
6. Department of Hematology, the First Hospital of Zhengzhou University, Zhengzhou 450000, China.
7. Department of Hematology, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.
8. Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital to Academy of Military Medical Sciences, Beijing 100071, China.
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Lymphoma, T-Cell, Angioimmunoblastic;
Survival analysis
- MeSH:
Adult;
Female;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Lymphoma, T-Cell/therapy*;
Male;
Middle Aged;
Retrospective Studies;
Transplantation, Autologous;
Transplantation, Homologous;
Treatment Outcome
- From:
Chinese Journal of Hematology
2019;40(7):573-577
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate clinical outcomes of autologous (auto-HSCT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) for angioimmunoblastic T-cell lymphoma (AITL) . Methods: From June 2007 to June 2017, clinical data of AITL patients who underwent HSCT in eight hospitals were assessed retrospectively. Results: Of 19 patients, 13 male and 6 female with a median age of 50 (32-60) years old, 12 auto-HSCT and 7 allo-HSCT recipients were enrolled in this study, all donors were HLA-identical siblings. Two of allo-HSCT recipients were relapsed auto-HSCT ones. There were 5 patients (5/12) in complete response (CR) status and 7 (7/12) in partial remission (PR) status before transplantation in auto-HSCT group, and 2 (2/7) in PR status and 3 (3/7) in progression disease (PD) status before transplantation in allo-HSCT group. The median follow-up for the surviving patients was 46.5 months (range, 1-100 months) for the whole series, two patients lost in auto-HSCT group. Three patients developed acute graft-versus-host disease (aGVHD) and 5 chronic graft-versus-host disease (cGVHD) after allo-HSCT. Three patients died of primary disease and 1bleeding in auto-HSCT group. One patient died of primary disease and 2 transplantation-related mortality in allo-HSCT group. The 3-year cumulative overall survival (OS) were 56% (95%CI 32%-100%) and 57% (95%CI 30%-100%) for auto-HSCT and allo-HSCT, respectively (P=0.979) . The 3-year cumulative progression-free survival (PFS) were 34% (95%CI 14%-85%) and 57% (95%CI 30%-100%) for auto-HSCT and allo-HSCT, respectively (P=0.451) . Conclusion: Both auto-HSCT and allo-HSCT were optimal choices for AITL. In clinical practice, which HSCT was better for AITL patients should be based on comprehensive factors including sensitivity to chemotherapy, risk stratification and disease status at transplantation.
